Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 127Carcinoma, Non-Small-Cell Lung 57Squamous Cell Carcinoma of Head and Neck 46Neoplasms 41Head and Neck Neoplasms 38Neoplasm Metastasis 31Pancreatic Neoplasms 15Colonic Neoplasms 14Lung Neoplasms 13Carcinoma, Squamous Cell 13Breast Neoplasms 13Rectal Neoplasms 12Recurrence 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Melanoma 7Stomach Neoplasms 6Carcinoma, Renal Cell 6Carcinoma 6Solid Tumors 5Gastrointestinal Neoplasms 5Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Neoplasms, Squamous Cell 4Laryngeal Diseases 4Advanced Solid Tumor 4Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Pancreatic Ductal 3Uterine Cervical Neoplasms 2

Interventions

Irinotecan 5Bevacizumab 5Leucovorin 4Fluorouracil 45,10-methylenetetrahydrofolic acid 3Oxaliplatin 2Levoleucovorin 2Drug Therapy 2Cetuximab 2trametinib 1spartalizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1nazartinib 1napabucasin 1encorafenib 1canakinumab 1alectinib 1Tinzaparin 1Radiotherapy 1Pemetrexed 1Ocoxin 1Mass Screening 1KRN-330 1Folfox protocol 1Capecitabine 1Artesunate 1ABT-165 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Intestinal Neoplasms × Cetuximab × Clear all
NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Pfizer

Phase 3 Active not recruiting
831 enrolled 2 FDA
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT01134666 2017-06-09

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Merck KGaA, Darmstadt, Germany

Terminated
165 enrolled
Gastrointestinal

Intestinal Neoplasms, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡